2011 Press releases


Displaying 1 - 10 of 25



12 December 2011
Promising interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with early stage acute myeloid leukaemia (AML) presented at ASH annual meeting

Clavis Pharma ASA (OSE: CLAVIS) announces that promising interim efficacy data from its Phase II clinical trial with elacytarabine in combination with idarubicin in patients with early stage acute myeloid leukaemia (AML) ...


28 October 2011
Clavis Pharma’s Financial Calendar 2012

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces its Financial Calendar for 2012.


27 October 2011
Clavis Pharma Third Quarter 2011

Clavis Pharma ASA (OSE: CLAVIS); the Norwegian cancer drug development company, announces today its results for the third quarter ...


24 October 2011
Clavis Pharma announces the completion of Study 002 Low hENT1 cut-off level determined for pivotal LEAP study of CP-4126 in patients with pancreatic cancer

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces the establishment of the cut-off level for defining hENT1 low vs. high expression that will be used to assess the results ...


20 October 2011
Invitation to presentation and webcast of Clavis Pharma's third quarter results 2011

Clavis Pharma ASA (OSE: CLAVIS) releases the company's third quarter 2011 results on Thursday 27 October 2011 at ...


27 September 2011
Clavis Pharma to present at Jefferies 2011 Global Healthcare Conference in London, UK.

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that the CEO, Olav Hellebø, will give a company presentation to investors at Jefferies 2011 Global Healthcare Conference in London, UK.



25 August 2011
Clavis Pharma expands Phase III CLAVELA study in patients with acute myeloid leukaemia (AML)

Clavis Pharma ASA (OSE: CLAVIS); the Norwegian cancer drug development company, announces today that is has decided to expand its pivotal Phase III CLAVELA study, investigating elacytarabine...